WO1990013332A1 - Stent with sustained drug delivery - Google Patents
Stent with sustained drug delivery Download PDFInfo
- Publication number
- WO1990013332A1 WO1990013332A1 PCT/US1990/002497 US9002497W WO9013332A1 WO 1990013332 A1 WO1990013332 A1 WO 1990013332A1 US 9002497 W US9002497 W US 9002497W WO 9013332 A1 WO9013332 A1 WO 9013332A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stent
- duct
- vessel
- pharmaceutical agent
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
Definitions
- This invention relates generally to a mechanical support or stent containing pharmaceutical agents, and a method of using the same. More particularly, this inven ⁇ tion relates to a stent containing pharmaceutical agents to be placed in a blood vessel where it preserves luminal dilation and releases agents that prevent arterial throm ⁇ bosis, platelet aggregation, and/or excessive endothelial cell proliferation at the implant site; or to be placed in a blood vessel, bile duct, ureter, fallopian tube or other duct or vessel where it delivers pharmaceutical agents to specific body sites or organs.
- Atherosclerotic cardiovascular disease Despite steady progress in treatment and prevention, atherosclerotic cardiovascular disease remains the most common cause of death in industrialized countries. (AJR 150:1263-1269 (1988)). Although surgical methods of treating atherosclerosis, such as prosthetic replacement of the aorta and cardiac valves and coronary bypass surgery, have resulted in significant medical advancement, a need continues to exist for treatment with less expen ⁇ sive and less invasive techniques.
- Percutaneous transluminal angioplasty or balloon angioplasty, of peripheral and coronary arteries has proven to be a useful nonsurgical procedure for the treatment of localized occlusive arterial lesions due to atherosclerosis.
- the technique consists of inserting an uninflated balloon- tipped catheter into the affected artery. Dilation of the diseased segment of artery is accomplished by inflating the balloon which pushes the sclerotic lesion outward, thereby enlarging the arterial diameter. The balloon is then deflated and the catheter is withdrawn. Following PTA, blood flow through the artery is typically significantly improved.
- Intravascular stents function by opposing recoil of elastic vascular stenoses after angioplasty has failed. They are also intended to provide a framework and support for arterial lesions that are likely to dissect after PTA. Although intravascular stents may be quite varied in design, they have been constructed of alloys of nickel and titanium (Id.), tempered stainless steel (Id.), plastic (Radiology 162:276-278 (1987)), or polyester fTx. Heart Inst. J. 15:12 (1988)), and have three basic mechanisms of action: thermal memory, spring load, and plastic deforma ⁇ tion. (AJR, 150:1263-1269 (1988)). Stents have been used to maintain the patency of many other ducts or vessels as well.
- Stents placed in the ureter have been described for treatment of obstructions due to benign and malignant lesions. (J. of Urology 130:553-554 (1983)). As a method of nonoperative drainage in the case of obstructive jaundice, stents have been placed in the bile ducts for percutaneous drainage of the biliary system. (Gastrointest. Radiol. 10:394-396) (1985)) .
- Drug therapy now exists that can prolong useful life in persons diagnosed with cancer. Drug development for cancer began with the accidental identification of the antitumor activity of nitrogen mustard, and its success in the treatment of Hodgkin's disease and lymphocytic lymphomas. .Principles of Internal Medicine 9th Ed. p. 1601.) Since the 1950's when it was recognized that a standardized approach to the development of anticancer drugs was needed, many substances have been identified as having antitumor activity. Most of these drugs however, require systemic treatment which destroys cancer cells but also has adverse effects or toxicities on normal cells. A need continues for a method of drug delivery that would destroy cancer cells but not harm normal cells.
- the conventional methods of drug therapy including tablets, capsules, slow-release formulations and injectables, all result in typical fluctuations of drug concentrations in the blood and body tissues.
- the drug is in tablet or capsule form for example, it dissolves and releases the drug in high concentrations in the stomach; as the drug begins to be absorbed, its concentration in the body rapidly rises to a peak, followed by a decline related to its characteristic metabolism and elimination. With every dose of the drug, concentrations may alternately reach levels that produce adverse side effects and then decline to values significantly less than therapeutic.
- potent agents destined to treat specific organs must travel through the blood stream in much larger concentrations than those required at the target tissue. (Med. Res. Rev. , l(4):373-386 (1981)).
- the present invention provides a stent with sustained drug release capabilities which is believed to avoid the cited disadvantages of the prior art structures and methods.
- a second objective of the invention is to provide a stent that can be placed in a vessel or duct and deliver a pharmaceutical agent to a specific body site or organ, thereby minimizing the systemic effect of these agents and adverse or toxic effects on other cells.
- the mechanical support or stent of this invention may be formed from any of the materials employed in the prior art that are non-toxic to the blood and body tissue and otherwise biocompatable.
- the stent may be in the form of any structure that successfully preserves the luminal diameter of a vessel or duct, and may operate by any mechanism known in the art.
- the pharmaceutical agents suitable to be employed in this invention are too numerous to list.
- the agents may be anticoagulants, antiplatelet substances, antispasmodics or drugs that inhibit excessive endothelial cell growth, or they may be antimicrobial agents, hormones or anticancer drugs, or any combination of these agents, or any others to accomplish any other localized purpose.
- the precise coating or impregnating of the stent with the pharmaceutical agent will vary depending on the form and material of the stent- and upon the pharmaceutical agent employed.
- the stent In use, the stent is placed into the vessel or duct so that it is in communication with the blood or other body fluid by means described in the art.
- a preferable means is the catheter insertion method as described by Fischell et al in U.S. Patent No. 4,768,507.
- an intravascular stent may contain heparin, aspirin, prostacyclin or an analog which when released by the stent, results in inhibition of thrombus formation or excessive endothelial cell growth.
- an intravascular stent may contain antitumor drugs, which, when released, result in antitumor activity.
- a stent By constructing a stent according to the above invention, several advantages may be realized. First, placement of the stent within a vessel will release anticoagulants, antiplatelet drugs or drugs that inhibit excessive endothelial cell growth at the placement site, thereby preserving the vessels patency and inhibiting luminal narrowing. Second, placement of a stent containing pharmaceutical agents, will deliver the agents to the placement site and/or to a specific body site or organ, thereby minimizing the systemic effect of these agents and adverse or toxic effects on other cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Prostheses (AREA)
Abstract
A mechanical support or stent containing pharmaceutical agents. The stent can be placed in the wall of a blood vessel where it releases pharmaceutical agents to prevent arterial thromboses, platelet aggregation and/or excessive endothelial cell proliferation at the placement site. The stent may also be placed in a blood vessel, bile duct, ureter, or fallopian tube or other duct or vessel, so that it delivers drugs to specific body sites or organs.
Description
DESCRIPTION
Stent With Sustained Drug Delivery
This invention relates generally to a mechanical support or stent containing pharmaceutical agents, and a method of using the same. More particularly, this inven¬ tion relates to a stent containing pharmaceutical agents to be placed in a blood vessel where it preserves luminal dilation and releases agents that prevent arterial throm¬ bosis, platelet aggregation, and/or excessive endothelial cell proliferation at the implant site; or to be placed in a blood vessel, bile duct, ureter, fallopian tube or other duct or vessel where it delivers pharmaceutical agents to specific body sites or organs.
Background
Despite steady progress in treatment and prevention, atherosclerotic cardiovascular disease remains the most common cause of death in industrialized countries. (AJR 150:1263-1269 (1988)). Although surgical methods of treating atherosclerosis, such as prosthetic replacement of the aorta and cardiac valves and coronary bypass surgery, have resulted in significant medical advancement, a need continues to exist for treatment with less expen¬ sive and less invasive techniques.
Percutaneous transluminal angioplasty (PTA) , or balloon angioplasty, of peripheral and coronary arteries has proven to be a useful nonsurgical procedure for the treatment of localized occlusive arterial lesions due to atherosclerosis. (Merck Manual. 15th Ed., p. 559). The technique consists of inserting an uninflated balloon- tipped catheter into the affected artery. Dilation of the diseased segment of artery is accomplished by inflating the balloon which pushes the sclerotic lesion outward, thereby enlarging the arterial diameter. The balloon is then deflated and the catheter is withdrawn.
Following PTA, blood flow through the artery is typically significantly improved. Unfortunately, however, although more than 90% of dilations are initially success¬ ful, there is a high rate of early failure or later restenosis. About one-third of all patients treated with PTA return for a second or third procedure, thus reducing the long-term benefits of the procedure. (Eur. Heart J. 9:31-37 (1988)).
Some researchers have found most vessels that occluded after PTA revealed disrupted intima and a medial tear that extended to the internal elastic lamina, and that platelet deposition was extensive giving rise to early thrombosis. (Tex. Heart Inst. J. 15(1):12-16
(1988)). Longer balloon inflation times, high doses of calcium-channel blockers, steroids, and other drug regimens have been attempted, but so far have proved unsuccessful in combating this problem. (NEJM 316:701
(1987)) .
To increase the long-term benefits of PTA, with the aim of preventing restenosis and sudden closuie of diseased arteries after angioplasty, various intravascular prosthetic devices have been developed that can be placed across the freshly-dilated lesion.
Mechanical intraluminal stents have been suggested as an adjunct to PTA in the treatment of atherosclerosis. In
1969, Dotter et al., reported the first non-operative placement of coiled, stainless steel, wire stents in the arteries of dogs. (Invest. Radiol. 4:329-332 (1969).
Fourteen years later, several reports on intravascular stents were published. (Radiology 147:261-263 (1983) ;
Radiology 147:259-260 (1983); Radiology 152:659-663
(1984); Radiology 156:69-72 (1985); Radiology 156:73-77
(1985)). And recently Fischell et al. disclosed an invention for a coil spring intravascular stent. (U.S. Patent No. 4,768,507, issued September 6, 1988).
Intravascular stents function by opposing recoil of elastic vascular stenoses after angioplasty has failed.
They are also intended to provide a framework and support for arterial lesions that are likely to dissect after PTA. Although intravascular stents may be quite varied in design, they have been constructed of alloys of nickel and titanium (Id.), tempered stainless steel (Id.), plastic (Radiology 162:276-278 (1987)), or polyester fTx. Heart Inst. J. 15:12 (1988)), and have three basic mechanisms of action: thermal memory, spring load, and plastic deforma¬ tion. (AJR, 150:1263-1269 (1988)). Stents have been used to maintain the patency of many other ducts or vessels as well. Stents placed in the ureter have been described for treatment of obstructions due to benign and malignant lesions. (J. of Urology 130:553-554 (1983)). As a method of nonoperative drainage in the case of obstructive jaundice, stents have been placed in the bile ducts for percutaneous drainage of the biliary system. (Gastrointest. Radiol. 10:394-396) (1985)) .
Although most of the previously employed stents exhibited long-term patency of the vessel, failure common¬ ly occurred when excessive endothelial cell growth caused significant narrowing of the lumen. (Radiology. 162:469- 472 (1987)). In addition, thrombus formation in small diameter stents has been shown to reduce the lumen diameter and decrease blood flow. (Radiology 102:276-278 (1987)). A need exists therefore, for a stent that retains vessel patency as well as inhibits luminal narrowing.
To date, the placement of intravascular stents in humans has required extensive systemic anticoagulant treatment in an attempt to diminish thrombogenicity of the stents. Sigwart et al report the administration of oral anticoagulants (acenocoumarin) and antiplatelet drugs for at least three months following stent placement. (Eur. Heart J. 9:31-37 (1988)). As with many systemically administered anticoagulants, the chief complication is overdose and the resulting abnormal bleeding which
predisposes to massive hemorrhage if left unchecked. (Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., 1975). Because of this risk, improvements of stent technology are necessary. Among the other complications encountered with the use of stents in humans were local spasms which occurred immediately after stent placement. To prevent these vasospasms, one researcher reports using nifedipine three times per day for three months. (Eur. Heart J.. supra at 32.) Obviously avoidance of the systemic use of these antispasmotics would also be desirable.
Drug therapy now exists that can prolong useful life in persons diagnosed with cancer. Drug development for cancer began with the accidental identification of the antitumor activity of nitrogen mustard, and its success in the treatment of Hodgkin's disease and lymphocytic lymphomas. .Principles of Internal Medicine 9th Ed. p. 1601.) Since the 1950's when it was recognized that a standardized approach to the development of anticancer drugs was needed, many substances have been identified as having antitumor activity. Most of these drugs however, require systemic treatment which destroys cancer cells but also has adverse effects or toxicities on normal cells. A need continues for a method of drug delivery that would destroy cancer cells but not harm normal cells.
Additionally, the conventional methods of drug therapy, including tablets, capsules, slow-release formulations and injectables, all result in typical fluctuations of drug concentrations in the blood and body tissues. If the drug is in tablet or capsule form for example, it dissolves and releases the drug in high concentrations in the stomach; as the drug begins to be absorbed, its concentration in the body rapidly rises to a peak, followed by a decline related to its characteristic metabolism and elimination. With every dose of the drug, concentrations may alternately reach levels that produce adverse side effects and then decline
to values significantly less than therapeutic. As a result, in order to be effective, potent agents destined to treat specific organs must travel through the blood stream in much larger concentrations than those required at the target tissue. (Med. Res. Rev. , l(4):373-386 (1981)). A need exists therefore, for new types of drug delivery methods, to assure an adequate therapeutic effect while reducing or eliminating side effects.
Summary Of The Invention The present invention provides a stent with sustained drug release capabilities which is believed to avoid the cited disadvantages of the prior art structures and methods.
Thus it is the objective of the present invention to provide an intravascular stent that preserves vessel patency and inhibits luminal narrowing.
A second objective of the invention is to provide a stent that can be placed in a vessel or duct and deliver a pharmaceutical agent to a specific body site or organ, thereby minimizing the systemic effect of these agents and adverse or toxic effects on other cells.
Detailed Description Of The Invention
The mechanical support or stent of this invention may be formed from any of the materials employed in the prior art that are non-toxic to the blood and body tissue and otherwise biocompatable. The stent may be in the form of any structure that successfully preserves the luminal diameter of a vessel or duct, and may operate by any mechanism known in the art. The pharmaceutical agents suitable to be employed in this invention are too numerous to list. The agents may be anticoagulants, antiplatelet substances, antispasmodics or drugs that inhibit excessive endothelial cell growth, or they may be antimicrobial agents, hormones or anticancer drugs, or any combination of these agents, or
any others to accomplish any other localized purpose. The precise coating or impregnating of the stent with the pharmaceutical agent will vary depending on the form and material of the stent- and upon the pharmaceutical agent employed.
In use, the stent is placed into the vessel or duct so that it is in communication with the blood or other body fluid by means described in the art. A preferable means is the catheter insertion method as described by Fischell et al in U.S. Patent No. 4,768,507.
Thereafter, blood or other body fluids will come into contact with the stent which will release a sustained amount of the pharmaceutical agent at the placement site, and/or to specific tissues or organs. In a preferred embodiment of the invention, an intravascular stent may contain heparin, aspirin, prostacyclin or an analog which when released by the stent, results in inhibition of thrombus formation or excessive endothelial cell growth. In another embodiment, an intravascular stent may contain antitumor drugs, which, when released, result in antitumor activity.
By constructing a stent according to the above invention, several advantages may be realized. First, placement of the stent within a vessel will release anticoagulants, antiplatelet drugs or drugs that inhibit excessive endothelial cell growth at the placement site, thereby preserving the vessels patency and inhibiting luminal narrowing. Second, placement of a stent containing pharmaceutical agents, will deliver the agents to the placement site and/or to a specific body site or organ, thereby minimizing the systemic effect of these agents and adverse or toxic effects on other cells.
Other and further embodiments of the invention are readily apparent from the above description of the invention, and these embodiments are believed to be within the scope of the invention.
Claims
1. A stent for placing in a vessel or duct which comprises: a. a support means that preserves the luminal diameter of said vessel or duct; and b. said means containing at least one pharmaceutical agent capable of sustained release from the stent.
2. A stent according to claim 1 wherein the vessel or duct is an artery, vein, bile duct, ureter, fallopian tube, or pancreatic duct.
3. A stent according to claim 1 wherein the support means is made of alloys of nickel and titanium,, stainless steel, plastic or polyester.
4. A stent according to claim 1 wherein the support means functions to preserve the luminal diameter of a vessel by thermal memory, spring load or plastic deformation.
5. A stent according to claim 1 wherein the pharmaceutical agent is an anticoagulant, antiplatelet substance, antispasmotic, drug that inhibits excessive cell proliferation, antimicrobial agent, hormone, anti¬ tumor drug, calcium channel blocker or antiarhythmic drug.
6. A method for the sustained release of at least one pharmaceutical agent into a bodily fluid, which comprises: a. placing a stent containing said pharmaceutical agent(s) into a vessel or duct; b. said stent being in contact with the fluid in said vessel or duct; and c. said stent thereby releasing said pharmaceutical agent(s) into said fluid.
7. A method according to claim 6 wherein the pharmaceutical agent is anticoagulant, antiplatelet substance, antispasmotic, drug that inhibits excessive cell proliferation, antimicrobial agent, hormone, antitumor drug, calcium channel blocker or antiarhythmic drug.
8. A method according to claim 6 wherein the bodily fluid is blood, urine or bile.
9. A method according to claim 6 wherein the stent is made of alloys of nickel and titanium, stainless steel, plastic or polyester.
10. A method according to claim 6 wherein the stent functions by thermal memory, spring load or plastic deformation.
11. A method acording to claim 6 wherein the vessel or duct is an artery, vein, bile duct, fallopian tube, or pancreatic duct.
12. A method according to claim 6 wherein the stent is placed into a vessel or duct by catheter insertion.
13. A method for treating atherosclerotic cardiovascular disease comprising: a. placing a stent containing at least one pharmaceutical agent into a blood vessel; b. said stent being in contact with the blood in said vessel; and c. said stent thereby releasing said pharmaceutical agent(s) into said blood and to the placement site.
14. A method according to claim 13 wherein the stent is made of alloys of nickel and titanium, stainless steel, plastic or polyester.
15. A method according to claim 13 wherein the stent functions by thermal memory, spring load or plastic deformation.
16. A method according to claim 13 wherein the pharmaceutical agent is an anticoagulant, antiplatelet drug, antispasmotic, or drug that inhibits excessive endothelial cell proliferation.
17. A method according to claim 13 wherein the blood vessel is a peripheral or coronary artery.
18. A method according to claim 13 wherein the stent is placed into the blood vessel by catheter insertion.
19. A method for treating tumors comprising: a. placing a stent containing a least one anti¬ tumor agent into a vessel or duct; b. said stent being in contact with the fluid in the vessel or duct; and c. said stent thereby releasing said antitumor agent(s) into said fluid and to said tumor.
20. A method according to claim 19 wherein the stent is made of alloys of nickel and titanium, stainless steel, plastic or polyester.
21. A method according to claim 19 wherein the stent functions by thermal memory, spring load or plastic deformation.
22. A method according to claim 19 wherein the vessel or duct is an artery, vein, bile duct, ureter, fallopian tube, or pancreatic duct.
23. A method according to claim 19 wherein the stent is placed into the vessel or duct by catheter insertion.
24. A method for treating a diseased organ or tissue comprising: a. placing a stent containing at least one pharmaceutical agent into a vessel or duct; b. said stent being in contact with the fluid in the vessel or duct; and c. said stent thereby releasing said pharmaceutical agent(s) into said fluid and to said diseased organ or tissue.
25. A method according to claim 24 wherein the stent is made of alloys of nickel and titanium, stainless steel, plastic or polyester.
26. A method according to claim 24 wherein the stent functions by thermal memory, springload or plastic deformation.
27. A method according to claim 24 wherein the vessel or duct is an artery, vein, bile duct, ureter, fallopian tube, or pancreatic duct.
28. A method according to claim 24 wherein the pharmaceutical agent is an antimicrobial agent, or anti¬ tumor agent.
29. A method according to claim 24 wherein the stent is placed into the vessel by catheter insertion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US350,389 | 1989-05-11 | ||
US35038989 | 1989-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990013332A1 true WO1990013332A1 (en) | 1990-11-15 |
Family
ID=32230036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/002497 WO1990013332A1 (en) | 1989-05-11 | 1990-05-09 | Stent with sustained drug delivery |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1990013332A1 (en) |
Cited By (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991012779A1 (en) * | 1990-02-28 | 1991-09-05 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
EP0501772A1 (en) * | 1991-02-28 | 1992-09-02 | SURGICAL SYSTEMS & INSTRUMENTS Inc. | Low restonosis atherectomy system |
EP0578998A1 (en) * | 1992-07-08 | 1994-01-19 | Strecker, Ernst Peter, Dr.-med.Prof. | Implantable percutaneous endoprosthesis |
US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5510077A (en) * | 1992-03-19 | 1996-04-23 | Dinh; Thomas Q. | Method of making an intraluminal stent |
US5554182A (en) * | 1992-03-19 | 1996-09-10 | Medtronic, Inc. | Method for preventing restenosis |
US5591224A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Bioelastomeric stent |
US5591227A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Drug eluting stent |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US5824048A (en) * | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
US5833651A (en) * | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US5997468A (en) * | 1990-02-28 | 1999-12-07 | Medtronic, Inc. | Intraluminal drug eluting prosthesis method |
WO2000002501A1 (en) | 1998-07-13 | 2000-01-20 | William Harvey Research Limited | Stent containing copper |
US6080190A (en) * | 1992-03-19 | 2000-06-27 | Medtronic, Inc. | Intraluminal stent |
US6120847A (en) * | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6156373A (en) * | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6206914B1 (en) | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
WO2001021229A1 (en) * | 1999-09-23 | 2001-03-29 | Lee Clarence C | Antimicrobial and anti-inflammatory endovascular (cardiovascular) stent |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6471980B2 (en) | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
EP1319416A1 (en) | 2001-12-12 | 2003-06-18 | Hehrlein, Christoph, Dr. | Porous metallic stent with a ceramic coating |
WO2005030287A1 (en) * | 2003-09-19 | 2005-04-07 | Julius-Maximilians- Universität Würzburg | Agent-releasing vascular prosthesis |
WO2005122959A2 (en) | 2004-06-08 | 2005-12-29 | Advanced Stent Technologies, Inc. | Stent with protruding branch portion for bifurcated vessels |
US7018405B2 (en) | 2000-12-22 | 2006-03-28 | Avantec Vascular Corporation | Intravascular delivery of methylprednisolone |
US7091213B2 (en) | 2002-02-01 | 2006-08-15 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds and uses thereof |
US7125866B1 (en) | 1999-04-30 | 2006-10-24 | Regents Of The University Of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
JP2006328086A (en) * | 1993-07-19 | 2006-12-07 | Angiotech Pharmaceuticals Inc | Anti-angiogenesis composition and stent coated therewith |
US7276348B2 (en) | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
WO2007146167A1 (en) | 2006-06-09 | 2007-12-21 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7326571B2 (en) | 2003-07-17 | 2008-02-05 | Boston Scientific Scimed, Inc. | Decellularized bone marrow extracellular matrix |
WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
WO2008112553A1 (en) | 2007-03-09 | 2008-09-18 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
WO2008147815A1 (en) | 2007-05-22 | 2008-12-04 | Chemocentryx, Inc. | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines |
WO2008147822A1 (en) | 2007-05-22 | 2008-12-04 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
EP1669091A3 (en) * | 1995-02-15 | 2009-06-17 | Boston Scientific Limited | Therapeutic inhibitor of vascular smooth muscle cells |
US7572600B2 (en) | 2004-08-04 | 2009-08-11 | Chemocentryx, Inc. | Enzymatic activities in chemokine-mediated inflammation |
US7572788B2 (en) | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7638624B2 (en) | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
US7683046B2 (en) | 1999-04-30 | 2010-03-23 | The Regents Of The University Of Michigan | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders |
WO2010064222A2 (en) | 2008-12-01 | 2010-06-10 | University College Cork, National University Of Ireland, Cork | Igf1 for myocardial repair |
US7759338B2 (en) | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
US7819912B2 (en) | 1998-03-30 | 2010-10-26 | Innovational Holdings Llc | Expandable medical device with beneficial agent delivery mechanism |
US7850728B2 (en) | 2000-10-16 | 2010-12-14 | Innovational Holdings Llc | Expandable medical device for delivery of beneficial agent |
WO2011119883A1 (en) | 2010-03-24 | 2011-09-29 | Advanced Bifurcation Systems, Inc. | Stent alignment during treatment of a bifurcation |
EP2422788A2 (en) | 2004-09-07 | 2012-02-29 | The Regents Of The University Of Michigan | Benzodiazepines and compositions and uses thereof |
US8187321B2 (en) | 2000-10-16 | 2012-05-29 | Innovational Holdings, Llc | Expandable medical device for delivery of beneficial agent |
US8197881B2 (en) | 2003-09-22 | 2012-06-12 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
US8349390B2 (en) | 2002-09-20 | 2013-01-08 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US8361537B2 (en) | 1998-03-30 | 2013-01-29 | Innovational Holdings, Llc | Expandable medical device with beneficial agent concentration gradient |
US8496967B2 (en) | 2006-11-14 | 2013-07-30 | Ariad Pharmaceuticals, Inc. | Oral formulations |
WO2014089495A1 (en) | 2012-12-07 | 2014-06-12 | Chemocentryx, Inc. | Diazole lactams |
WO2014100735A2 (en) | 2012-12-21 | 2014-06-26 | Chemocentryx, Inc. | Diazole amides |
US8936567B2 (en) | 2007-11-14 | 2015-01-20 | Boston Scientific Scimed, Inc. | Balloon bifurcated lumen treatment |
WO2015084842A1 (en) | 2013-12-02 | 2015-06-11 | Chemocentryx, Inc. | Ccr6 compounds |
US9066990B2 (en) | 2001-03-26 | 2015-06-30 | Bayer Intellectual Property Gmbh | Preparation for restenosis prevention |
US9126978B2 (en) | 2009-11-17 | 2015-09-08 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
WO2015134998A1 (en) | 2014-03-07 | 2015-09-11 | Biocryst Pharmaceuticals, Inc. | Human plasma kallikrein inhibitors |
US9561126B2 (en) | 1996-11-04 | 2017-02-07 | Boston Scientific Scimed, Inc. | Catheter with attached flexible side sheath |
US9649476B2 (en) | 2002-09-20 | 2017-05-16 | Bayer Intellectual Property Gmbh | Medical device for dispersing medicaments |
EP3167845A1 (en) | 2015-11-12 | 2017-05-17 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin | An implantable biocompatible expander suitable for treatment of constrictions of body lumen |
WO2017087607A1 (en) | 2015-11-19 | 2017-05-26 | Chemocentryx, Inc. | Modulators of chemokine receptors |
WO2017136395A1 (en) | 2016-02-01 | 2017-08-10 | Biocryst Pharmaceuticals, Inc. | Benzopyrazole compounds and analogues thereof |
DE202011111004U1 (en) | 2010-03-24 | 2018-04-17 | Advanced Bifurcation Systems, Inc. | Systems for the ostial stenting of a bifurcation |
WO2018081513A1 (en) | 2016-10-31 | 2018-05-03 | Biocryst Pharmaceuticals, Inc. | Prodrugs of kallikrein inhibitors |
US10010400B2 (en) | 2015-03-30 | 2018-07-03 | Taris Biomedical Llc | Devices and methods for local delivery of drug to upper urinary tract |
WO2018232094A1 (en) | 2017-06-15 | 2018-12-20 | Biocryst Pharmaceuticals, Inc. | Imidazole-containing inhibitors of alk2 kinase |
US10219927B2 (en) | 2008-09-25 | 2019-03-05 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation |
US10219926B2 (en) | 2008-09-25 | 2019-03-05 | Advanced Bifurcation Systems Inc. | Selective stent crimping |
EP3449879A1 (en) | 2011-02-08 | 2019-03-06 | Advanced Bifurcation Systems, Inc. | System for treating a bifurcation with a fully crimped stent |
WO2019060820A1 (en) | 2017-09-25 | 2019-03-28 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
US10406010B2 (en) | 2011-02-08 | 2019-09-10 | Advanced Bifurcation Systems Inc. | Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use |
EP3616655A1 (en) | 2010-03-24 | 2020-03-04 | Advanced Bifurcation Systems Inc. | Selective stent crimping |
WO2021026182A1 (en) | 2019-08-06 | 2021-02-11 | Biocryst Pharmaceuticals, Inc. | Process-scale synthesis of a plasma kallikrein inhibitor |
US11000392B2 (en) | 2008-09-25 | 2021-05-11 | Advanced Bifurcation Systems Inc. | Partially crimped stent |
EP3939658A1 (en) | 2018-04-06 | 2022-01-19 | Biocryst Pharmaceuticals, Inc. | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors |
US11267790B2 (en) | 2019-07-08 | 2022-03-08 | Rezolute, Inc. | Processes for preparing plasma kallikrein inhibitors |
US11298252B2 (en) | 2008-09-25 | 2022-04-12 | Advanced Bifurcation Systems Inc. | Stent alignment during treatment of a bifurcation |
EP4019022A1 (en) | 2015-10-01 | 2022-06-29 | BioCryst Pharmaceuticals, Inc. | Human plasma kallikrein inhibitors |
US11484398B2 (en) | 2019-11-22 | 2022-11-01 | ProVerum Limited | Implant delivery methods |
US11602621B2 (en) | 2019-11-22 | 2023-03-14 | ProVerum Limited | Device for controllably deploying expandable implants |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
US3948254A (en) * | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
US4321711A (en) * | 1978-10-18 | 1982-03-30 | Sumitomo Electric Industries, Ltd. | Vascular prosthesis |
US4642111A (en) * | 1982-02-12 | 1987-02-10 | Unitika Ltd. | Injector filled with an anti-cancer composition |
WO1989003232A1 (en) * | 1987-10-09 | 1989-04-20 | Bukh Meditec A/S | A medical device for introduction into a body cavity |
-
1990
- 1990-05-09 WO PCT/US1990/002497 patent/WO1990013332A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
US3948254A (en) * | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
US4321711A (en) * | 1978-10-18 | 1982-03-30 | Sumitomo Electric Industries, Ltd. | Vascular prosthesis |
US4642111A (en) * | 1982-02-12 | 1987-02-10 | Unitika Ltd. | Injector filled with an anti-cancer composition |
WO1989003232A1 (en) * | 1987-10-09 | 1989-04-20 | Bukh Meditec A/S | A medical device for introduction into a body cavity |
Cited By (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997468A (en) * | 1990-02-28 | 1999-12-07 | Medtronic, Inc. | Intraluminal drug eluting prosthesis method |
WO1991012779A1 (en) * | 1990-02-28 | 1991-09-05 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
EP0501772A1 (en) * | 1991-02-28 | 1992-09-02 | SURGICAL SYSTEMS & INSTRUMENTS Inc. | Low restonosis atherectomy system |
US5571166A (en) * | 1992-03-19 | 1996-11-05 | Medtronic, Inc. | Method of making an intraluminal stent |
US5510077A (en) * | 1992-03-19 | 1996-04-23 | Dinh; Thomas Q. | Method of making an intraluminal stent |
US5554182A (en) * | 1992-03-19 | 1996-09-10 | Medtronic, Inc. | Method for preventing restenosis |
US5591224A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Bioelastomeric stent |
US5591227A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Drug eluting stent |
US5599352A (en) * | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
US6080190A (en) * | 1992-03-19 | 2000-06-27 | Medtronic, Inc. | Intraluminal stent |
US5628785A (en) * | 1992-03-19 | 1997-05-13 | Medtronic, Inc. | Bioelastomeric stent |
US5697967A (en) * | 1992-03-19 | 1997-12-16 | Medtronic, Inc. | Drug eluting stent |
US6645241B1 (en) | 1992-07-08 | 2003-11-11 | Ernst Peter Strecker | Endoprosthesis that can be percutaneously implanted in the patient's body |
US6193746B1 (en) | 1992-07-08 | 2001-02-27 | Ernst Peter Strecker | Endoprosthesis that can be percutaneously implanted in the patient's body |
EP0578998A1 (en) * | 1992-07-08 | 1994-01-19 | Strecker, Ernst Peter, Dr.-med.Prof. | Implantable percutaneous endoprosthesis |
US5624411A (en) * | 1993-04-26 | 1997-04-29 | Medtronic, Inc. | Intravascular stent and method |
US5824048A (en) * | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
US5776184A (en) * | 1993-04-26 | 1998-07-07 | Medtronic, Inc. | Intravasoular stent and method |
US5837008A (en) * | 1993-04-26 | 1998-11-17 | Medtronic, Inc. | Intravascular stent and method |
US5679400A (en) * | 1993-04-26 | 1997-10-21 | Medtronic, Inc. | Intravascular stent and method |
US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
JP4597115B2 (en) * | 1993-07-19 | 2010-12-15 | アンジオテック ファーマシューティカルズ,インコーポレイテッド | Anti-angiogenic composition and stent coated therewith |
JP2007084572A (en) * | 1993-07-19 | 2007-04-05 | Angiotech Pharmaceuticals Inc | Anti-angiogenic composition and stent covered therewith |
JP2006328086A (en) * | 1993-07-19 | 2006-12-07 | Angiotech Pharmaceuticals Inc | Anti-angiogenesis composition and stent coated therewith |
EP1208818A2 (en) | 1994-09-15 | 2002-05-29 | Medtronic Inc. | Mold for making an intralumimal stent |
EP1669091A3 (en) * | 1995-02-15 | 2009-06-17 | Boston Scientific Limited | Therapeutic inhibitor of vascular smooth muscle cells |
US7220739B2 (en) | 1995-05-18 | 2007-05-22 | Regents Of The University Of Michigan | Therapeutic application of pro-apoptotic benzodiazepines |
US9561126B2 (en) | 1996-11-04 | 2017-02-07 | Boston Scientific Scimed, Inc. | Catheter with attached flexible side sheath |
US5833651A (en) * | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
US6228845B1 (en) | 1996-11-08 | 2001-05-08 | Medtronic, Inc. | Therapeutic intraluminal stents |
US6253443B1 (en) | 1997-09-30 | 2001-07-03 | Scimed Life Systems, Inc. | Method of forming a stent |
US7963990B2 (en) | 1997-09-30 | 2011-06-21 | Boston Scientific Scimed, Inc. | Stent drug delivery system |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US8052735B2 (en) | 1998-03-30 | 2011-11-08 | Innovational Holdings, Llc | Expandable medical device with ductile hinges |
US8623068B2 (en) | 1998-03-30 | 2014-01-07 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US8439968B2 (en) | 1998-03-30 | 2013-05-14 | Innovational Holdings, Llc | Expandable medical device for delivery of beneficial agent |
US8361537B2 (en) | 1998-03-30 | 2013-01-29 | Innovational Holdings, Llc | Expandable medical device with beneficial agent concentration gradient |
US8206435B2 (en) | 1998-03-30 | 2012-06-26 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US7896912B2 (en) | 1998-03-30 | 2011-03-01 | Innovational Holdings, Llc | Expandable medical device with S-shaped bridging elements |
US7819912B2 (en) | 1998-03-30 | 2010-10-26 | Innovational Holdings Llc | Expandable medical device with beneficial agent delivery mechanism |
US8052734B2 (en) | 1998-03-30 | 2011-11-08 | Innovational Holdings, Llc | Expandable medical device with beneficial agent delivery mechanism |
US6206914B1 (en) | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
WO2000002501A1 (en) | 1998-07-13 | 2000-01-20 | William Harvey Research Limited | Stent containing copper |
EP1426021A1 (en) | 1998-08-31 | 2004-06-09 | Medtronic, Inc. | Implantable system with drug eluting cells for on-demand local drug delivery |
US6120847A (en) * | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6656156B2 (en) | 1999-02-03 | 2003-12-02 | Scimed Life Systems, Inc. | Dual surface protection coating for drug delivery balloon catheters and stents |
US7276348B2 (en) | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
US8168626B2 (en) | 1999-04-30 | 2012-05-01 | The Regents Of The University Of Michigan | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders |
US7683046B2 (en) | 1999-04-30 | 2010-03-23 | The Regents Of The University Of Michigan | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders |
US7125866B1 (en) | 1999-04-30 | 2006-10-24 | Regents Of The University Of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
US7572788B2 (en) | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US6322847B1 (en) | 1999-05-03 | 2001-11-27 | Boston Scientific, Inc. | Medical device coating methods and devices |
US6156373A (en) * | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
WO2001021229A1 (en) * | 1999-09-23 | 2001-03-29 | Lee Clarence C | Antimicrobial and anti-inflammatory endovascular (cardiovascular) stent |
US7850728B2 (en) | 2000-10-16 | 2010-12-14 | Innovational Holdings Llc | Expandable medical device for delivery of beneficial agent |
US8187321B2 (en) | 2000-10-16 | 2012-05-29 | Innovational Holdings, Llc | Expandable medical device for delivery of beneficial agent |
US6471980B2 (en) | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
US7018405B2 (en) | 2000-12-22 | 2006-03-28 | Avantec Vascular Corporation | Intravascular delivery of methylprednisolone |
US9066990B2 (en) | 2001-03-26 | 2015-06-30 | Bayer Intellectual Property Gmbh | Preparation for restenosis prevention |
EP1319416A1 (en) | 2001-12-12 | 2003-06-18 | Hehrlein, Christoph, Dr. | Porous metallic stent with a ceramic coating |
US8058426B2 (en) | 2002-02-01 | 2011-11-15 | Ariad Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
US7709020B2 (en) | 2002-02-01 | 2010-05-04 | Ariad Pharmaceuticals, Inc. | Implantable device comprising phosphorus-containing macrolides |
US9024014B2 (en) | 2002-02-01 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
US7091213B2 (en) | 2002-02-01 | 2006-08-15 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds and uses thereof |
US7186826B2 (en) * | 2002-02-01 | 2007-03-06 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds and uses thereof |
US9254202B2 (en) | 2002-09-20 | 2016-02-09 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US8349390B2 (en) | 2002-09-20 | 2013-01-08 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US9649476B2 (en) | 2002-09-20 | 2017-05-16 | Bayer Intellectual Property Gmbh | Medical device for dispersing medicaments |
US7326571B2 (en) | 2003-07-17 | 2008-02-05 | Boston Scientific Scimed, Inc. | Decellularized bone marrow extracellular matrix |
US8790920B2 (en) | 2003-07-17 | 2014-07-29 | Boston Scientific Scimed, Inc. | Decellularized bone marrow extracellular matrix |
WO2005030287A1 (en) * | 2003-09-19 | 2005-04-07 | Julius-Maximilians- Universität Würzburg | Agent-releasing vascular prosthesis |
US8197881B2 (en) | 2003-09-22 | 2012-06-12 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
WO2005122959A2 (en) | 2004-06-08 | 2005-12-29 | Advanced Stent Technologies, Inc. | Stent with protruding branch portion for bifurcated vessels |
US7572600B2 (en) | 2004-08-04 | 2009-08-11 | Chemocentryx, Inc. | Enzymatic activities in chemokine-mediated inflammation |
EP2422788A2 (en) | 2004-09-07 | 2012-02-29 | The Regents Of The University Of Michigan | Benzodiazepines and compositions and uses thereof |
US7638624B2 (en) | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
US7759338B2 (en) | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
WO2007146167A1 (en) | 2006-06-09 | 2007-12-21 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
EP2418206A2 (en) | 2006-06-09 | 2012-02-15 | The Regents of the University of Michigan | Benzodiazepine derivatives useful in the treatment of autoimmune disorders |
WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
US8496967B2 (en) | 2006-11-14 | 2013-07-30 | Ariad Pharmaceuticals, Inc. | Oral formulations |
WO2008112553A1 (en) | 2007-03-09 | 2008-09-18 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
WO2008147815A1 (en) | 2007-05-22 | 2008-12-04 | Chemocentryx, Inc. | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines |
WO2008147822A1 (en) | 2007-05-22 | 2008-12-04 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
US8936567B2 (en) | 2007-11-14 | 2015-01-20 | Boston Scientific Scimed, Inc. | Balloon bifurcated lumen treatment |
US10918506B2 (en) | 2008-09-25 | 2021-02-16 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation |
US11839562B2 (en) | 2008-09-25 | 2023-12-12 | Advanced Bifurcation Systems Inc. | Partially crimped stent |
US11298252B2 (en) | 2008-09-25 | 2022-04-12 | Advanced Bifurcation Systems Inc. | Stent alignment during treatment of a bifurcation |
US11000392B2 (en) | 2008-09-25 | 2021-05-11 | Advanced Bifurcation Systems Inc. | Partially crimped stent |
US11426297B2 (en) | 2008-09-25 | 2022-08-30 | Advanced Bifurcation Systems Inc. | Selective stent crimping |
US10219927B2 (en) | 2008-09-25 | 2019-03-05 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation |
US10610391B2 (en) | 2008-09-25 | 2020-04-07 | Advanced Bifurcation Systems Inc. | Stent alignment during treatment of a bifurcation |
US11857442B2 (en) | 2008-09-25 | 2024-01-02 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation |
US10219926B2 (en) | 2008-09-25 | 2019-03-05 | Advanced Bifurcation Systems Inc. | Selective stent crimping |
EP4147681A1 (en) | 2008-09-25 | 2023-03-15 | Advanced Bifurcation Systems Inc. | Partially crimped stent |
WO2010064222A2 (en) | 2008-12-01 | 2010-06-10 | University College Cork, National University Of Ireland, Cork | Igf1 for myocardial repair |
EP3047861A2 (en) | 2008-12-01 | 2016-07-27 | University College Cork-National University of Ireland, Cork | Intracoronary infusion of igf-1 for myocardial repair |
US9126978B2 (en) | 2009-11-17 | 2015-09-08 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
US9849138B2 (en) | 2009-11-17 | 2017-12-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties |
EP4275660A2 (en) | 2010-03-24 | 2023-11-15 | Advanced Bifurcation Systems Inc. | Selective stent crimping |
DE202011111004U1 (en) | 2010-03-24 | 2018-04-17 | Advanced Bifurcation Systems, Inc. | Systems for the ostial stenting of a bifurcation |
EP3616655A1 (en) | 2010-03-24 | 2020-03-04 | Advanced Bifurcation Systems Inc. | Selective stent crimping |
WO2011119883A1 (en) | 2010-03-24 | 2011-09-29 | Advanced Bifurcation Systems, Inc. | Stent alignment during treatment of a bifurcation |
EP3777780A1 (en) | 2011-02-08 | 2021-02-17 | Advanced Bifurcation Systems Inc. | System for treating a bifurcation with a fully crimped stent |
US11000393B2 (en) | 2011-02-08 | 2021-05-11 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation with a fully crimped stent |
EP3449879A1 (en) | 2011-02-08 | 2019-03-06 | Advanced Bifurcation Systems, Inc. | System for treating a bifurcation with a fully crimped stent |
US10285832B2 (en) | 2011-02-08 | 2019-05-14 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation with a fully crimped stent |
US10406010B2 (en) | 2011-02-08 | 2019-09-10 | Advanced Bifurcation Systems Inc. | Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use |
US11717428B2 (en) | 2011-02-08 | 2023-08-08 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation with a fully crimped stent |
US11484424B2 (en) | 2011-02-08 | 2022-11-01 | Advanced Bifurcation Systems Inc. | Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use |
WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
WO2014089495A1 (en) | 2012-12-07 | 2014-06-12 | Chemocentryx, Inc. | Diazole lactams |
WO2014100735A2 (en) | 2012-12-21 | 2014-06-26 | Chemocentryx, Inc. | Diazole amides |
WO2015084842A1 (en) | 2013-12-02 | 2015-06-11 | Chemocentryx, Inc. | Ccr6 compounds |
EP3828173A1 (en) | 2014-03-07 | 2021-06-02 | BioCryst Pharmaceuticals, Inc. | Substituted pyrazoles as human plasma kallikrein inhibitors |
WO2015134998A1 (en) | 2014-03-07 | 2015-09-11 | Biocryst Pharmaceuticals, Inc. | Human plasma kallikrein inhibitors |
EP4180424A1 (en) | 2014-03-07 | 2023-05-17 | BioCryst Pharmaceuticals, Inc. | Substituted pyrazoles as human plasma kallikrein inhibitors |
US10010400B2 (en) | 2015-03-30 | 2018-07-03 | Taris Biomedical Llc | Devices and methods for local delivery of drug to upper urinary tract |
EP4019022A1 (en) | 2015-10-01 | 2022-06-29 | BioCryst Pharmaceuticals, Inc. | Human plasma kallikrein inhibitors |
WO2017081326A2 (en) | 2015-11-12 | 2017-05-18 | The Provost, Fellows, Fdn Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth | An implantable biocompatible expander suitable for treatment of constrictions of body lumen |
US10682245B2 (en) | 2015-11-12 | 2020-06-16 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin | Implantable biocompatible expander suitable for treatment of constrictions of body lumen |
US10881539B2 (en) | 2015-11-12 | 2021-01-05 | The Provost, Fellows, Foundation Scholars & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin | Implantable biocompatible expander suitable for treatment of constrictions of body lumen |
EP3167845A1 (en) | 2015-11-12 | 2017-05-17 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin | An implantable biocompatible expander suitable for treatment of constrictions of body lumen |
WO2017087607A1 (en) | 2015-11-19 | 2017-05-26 | Chemocentryx, Inc. | Modulators of chemokine receptors |
EP3925956A1 (en) | 2016-02-01 | 2021-12-22 | BioCryst Pharmaceuticals, Inc. | 1h-indazole-3-carboxamide derivatives and related compounds as factor d inhibitors for treating diseases characterized by aberrant complement system activity, such as e.g. immunological disorders |
WO2017136395A1 (en) | 2016-02-01 | 2017-08-10 | Biocryst Pharmaceuticals, Inc. | Benzopyrazole compounds and analogues thereof |
WO2018081513A1 (en) | 2016-10-31 | 2018-05-03 | Biocryst Pharmaceuticals, Inc. | Prodrugs of kallikrein inhibitors |
WO2018232094A1 (en) | 2017-06-15 | 2018-12-20 | Biocryst Pharmaceuticals, Inc. | Imidazole-containing inhibitors of alk2 kinase |
WO2019060820A1 (en) | 2017-09-25 | 2019-03-28 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
EP3939658A1 (en) | 2018-04-06 | 2022-01-19 | Biocryst Pharmaceuticals, Inc. | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors |
US11267790B2 (en) | 2019-07-08 | 2022-03-08 | Rezolute, Inc. | Processes for preparing plasma kallikrein inhibitors |
WO2021026182A1 (en) | 2019-08-06 | 2021-02-11 | Biocryst Pharmaceuticals, Inc. | Process-scale synthesis of a plasma kallikrein inhibitor |
US11484398B2 (en) | 2019-11-22 | 2022-11-01 | ProVerum Limited | Implant delivery methods |
US11602621B2 (en) | 2019-11-22 | 2023-03-14 | ProVerum Limited | Device for controllably deploying expandable implants |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1990013332A1 (en) | Stent with sustained drug delivery | |
US5342348A (en) | Method and device for treating and enlarging body lumens | |
Roubin et al. | Early and late results of intracoronary arterial stenting after coronary angioplasty in dogs. | |
US5419760A (en) | Medicament dispensing stent for prevention of restenosis of a blood vessel | |
Triller et al. | A comparison study of self-expandable stents vs balloon angioplasty alone in femoropopliteal artery occlusions | |
US7396538B2 (en) | Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device | |
US5242397A (en) | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty | |
Trent et al. | A balloon-expandable intravascular stent for obliterating experimental aortic dissection | |
WO1993004735A1 (en) | Method and apparatus for restenosis treatment | |
EP0691841B1 (en) | Medicament dispensing stents | |
Carrasco et al. | Use of the Gianturco self-expanding stent in stenoses of the superior and inferior venae cavae | |
Wong et al. | Intracoronary stenting in acute myocardial infarction | |
Reimers et al. | A word of caution on optimizing stent deployment in calcified lesions: acute coronary rupture with cardiac tamponade | |
Ellis et al. | Intracoronary stents: will they fulfill their promise as an adjunct to angioplasty? | |
Wolf et al. | Initial experience with the Palmaz stent for aortoiliac stenoses | |
US8876891B1 (en) | Drug eluting stent and a guide catheter device assembly for implanting the same | |
WO1998030255A9 (en) | Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels | |
WO1998030255A2 (en) | Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels | |
Smith et al. | Stent thrombosis in a patient receiving chemotherapy | |
ROGERS et al. | Controlled release of heparin reduces neointimal hyperplasia in stented rabbit arteries: Ramifications for local therapy | |
White et al. | Placement of “biliary” stents in saphenous vein coronary bypass grafts | |
ODA et al. | “Fork” stenting for bifurcational lesion | |
Evans et al. | Aortic laceration secondary to Palmaz stent placement for treatment of superior vena cava syndrome | |
Baldus et al. | Membrane‐covered stents for the treatment of aortocoronary vein graft disease | |
Yang et al. | Percutaneous endovascular stenting: development, investigation and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |